Basilea Pharmaceutica Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Basilea Pharmaceutica Stock Forecast and Price Target
Year-long price target forecasts from prominent analysts have recently been released for Basilea Pharmaceutica, with an average price target of CHF66.00. This potential gain of 61.37 percent from the previous closing price in April, 2024 is calculated on a high forecast of CHF105.00 and a low estimate of CHF40.50. Even if not interested in BSLN stock, you may want to be aware of its competitors.
61.37% Upside
Basilea Pharmaceutica Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Basilea Pharmaceutica's Price has increased by 100.00%, going from CHF0.00 to CHF0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach CHF43.54 – an increase of 100.00%. The Basilea Pharmaceutica forecast is for Fair Value to reach CHF74.47 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARGX Stock Forecast | argenx | Outperform |
4
|
337.10€ | Buy/Sell | 531.81€ | 30.23% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.03k | Buy/Sell | kr2.71k | 26.35% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
51.10€ | Buy/Sell | 48.61€ | -0.78% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.18 | Buy/Sell | £28.11 | 62.71% |
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr581.50 | Buy/Sell | kr357.00 | 40.15% |
Basilea Pharmaceutica Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Basilea Pharmaceutica's Revenue has increased by 15.78%, going from CHF127.63M to CHF147.77M. In the next year, analysts are expecting an increase in Revenue, predicting it will reach CHF172.36M – an increase of 16.64%. The Basilea Pharmaceutica forecast is for Revenue to reach CHF198.60M or grow by 34.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
33.00€ | Buy/Sell | 42.52€ | 27.27% |
| ALK B Stock Forecast | ALK-Abelló A/S | Outperform |
13
|
kr127.50 | Buy/Sell | kr109.25 | 4.31% |
| MOR Stock Forecast | MorphoSys | Outperform |
6
|
67.75€ | Buy/Sell | 28.78€ | 0.37% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EVT Stock Forecast | Evotec | Outperform |
14
|
13.70€ | Buy/Sell | 37.33€ | 86.13% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.06 | Buy/Sell | £28.89 | 109.16% |
| ALM Stock Forecast | Almirall | Outperform |
16
|
8.24€ | Buy/Sell | 11.39€ | 39.56% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF73.40 | Buy/Sell | CHF76.55 | 28.16% |
| FAE Stock Forecast | Faes Farma | Hold |
18
|
3.18€ | Buy/Sell | 3.90€ | 14.78% |
| PHM Stock Forecast | Pharma Mar | Outperform |
13
|
26.52€ | Buy/Sell | 50.20€ | 81.00% |
Basilea Pharmaceutica EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Basilea Pharmaceutica's EBITDA has grown, increasing from CHF-20.32M to CHF21.71M – a growth of 206.84%. The next year looks promising for Basilea Pharmaceutica, with analysts predicting EBITDA of CHF42.17M – an increase of 94.24%. Over the next seven years, experts anticipate that Basilea Pharmaceutica's EBITDA will grow at a rate of 339.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NIOX Stock Forecast | NIOX Group Plc | Outperform |
6
|
£0.66 | Buy/Sell | £0.76 | 16.67% |
| DBV Stock Forecast | DBV Technologies | Outperform |
5
|
1.21€ | Buy/Sell | 4.07€ | 230.58% |
| MOLN Stock Forecast | Molecular Partners | Outperform |
4
|
CHF3.30 | Buy/Sell | CHF9.50 | 183.33% |
Basilea Pharmaceutica EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Basilea Pharmaceutica's EBIT has grown by 197.20%, from CHF-21.41M to CHF20.81M. For the next year, analysts are expecting EBIT to reach CHF45.13M – an increase of 116.87%. Over the next seven years, experts predict that EBIT will grow by 345.94%.
Basilea Pharmaceutica EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Basilea Pharmaceutica's EPS has increased by 100.00%, going from CHF-2.89 to CHF0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach CHF2.96 – an increase of 100.00%. The Basilea Pharmaceutica forecast is for EPS to reach CHF6.64 or grow by 100.00%.
Site Navigation
.jpg)